Safety and risk communication to patients

Expert Opinion on Drug Safety

Volumn 5, Issue 6, 2006, Pages 747-750

  Thürmann, Petra A ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Drug information; Empowerment; Patient leaflet; Risk communication

Indexed keywords

ISOTRETINOIN; MEASLES MUMPS RUBELLA VACCINE;

DOCTOR PATIENT RELATION; DRUG INFORMATION; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; EMPOWERMENT; HUMAN; LAW SUIT; LIVER TOXICITY; MEASLES; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL ERROR; MUMPS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT INFORMATION; PATIENT PARTICIPATION; PATIENT SAFETY; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RUBELLA; SELF HELP; TREATMENT OUTCOME; VACCINATION;

COMMUNICATION; DRUG LABELING; HUMANS; PATIENT EDUCATION; PHARMACEUTICAL PREPARATIONS;

EID: 33750574360     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.6.747     Document Type: Editorial

References (28)

1. GEORGE CF, RABIN KH: Improving patient information and education on medicines. Report from the Foundation's Committee on Patient Information. Geneva, Switzerland. International Risk/Benefit Foundation-RAD-AR (1993) 10:14-15.
2. EDWARDS IR: Effective communications in pharmacovigilance. The Erice report. International conference on developing effective communications in pharmacovigilance, 24 - 27 September 1997. Erice, Sicily. Uppsala, Sweden: the Uppsala Monitoring Centre (1998):1-4.
3. BOWDLER J: The Erice declaration on communicating drug safety information. The Erice report. International conference on developing effective communications in pharmacovigilance, 24 - 27 September 1997. Erice, Sicily. Uppsala, Sweden: the Uppsala Monitoring Centre (1998):6.
4. NORA LM, BENVENUTI RJ: Medicolegal aspects of informed consent. Neurol. Clin. North Am. (1998) 16:207-215.
5. FADEN R, BEAUCHAMP TL: History and Theory of Informed Consent. Oxford University Press, New York (1986).
6. KÖBBERLING J, HAFFNER S: Rechtssicherheit und Rechtspraxis bei der Risikoaufklärung vor Arzneimittelgabe. Med. Klin. (2006) 101:516-523.
7. LEVINSON W, ROTER DL, MULLOOLY JP et al.: Physician- patient communication: the relationship with malpractice claims among primary care physicians and surgeons. JAMA (1997) 277:553-559.
8. MAZUR DJ: Influence of the law on risk and informed consent. Br. Med. J. (2003) 327:731-734.
9. NINK K, SCHRÖDER H: Zu Risiken und Nebenwirkungen: Lesen Sie die Packungsbeilage? WIdO-Materialen Bd. 53, Bonn (2005).
10. ENDE J, KAZIS L, ASH A, MOSKOWITZ MA: Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients. J. Gen. Intern. Med (1989) 4:23-30.
11. EDWARDS A, ELWYN G: Risks - listen and don't mislead. Br. J. Gen. Pract. (2001) 51:259-260.
12. EDWARDS A, ELWYN G, MULLEY A: Explaining risks: turning numerical data into meaningful pictures. Br. Med. J. (2002) 324:827-830.
13. BERRY DC, RAYNOR DK, KNAPP P, BERSELLINI E: Patients' understanding of risk associated with medication use: Impact of European commission guidelines and other risk scales. Drug Saf. (2003) 26(1):1-11.
14. BERRY DC, KNAPP P, RAYNOR DK: Provision of information about drug side-effects to patients. Lancet (2002) 359:853-854.
15. YAMAGISHI K: When a 12.86% mortality is more dangerous than 24.14%: implication for risk communcation. Appl. Cogn. Psychol. (1997) 11:495-506.
16. GIGERENZER G, EDWARDS A: Simple tools for understanding risks: from innumeracy to insight. Br. Med. J. (2003) 327:741-744.
17. PALING J: Strategies to help patients understand risks. Br. Med. J. (2003) 327:745-748.
18. ALASZEWSKI A: A person-centred approach to communicating risk. PloS Med. (2005) 2(2):93-95.
19. ALASZEWSKI A, HORLICK-JONES T: How can doctors communicate information about risk more effectively? Br. Med. J. (2003) 327:728-731.
20. WALLER PC, EVANS SJW, BEARD K: Drug safety and the media. Br. J. Clin. Pharmacol. (2005) 61:123-126.
21. OWENS SR: Injection on confidence: the recent controversy in the UK has led to falling MMR vaccination rates. EMBO Rep. (2002) 3:406-409.
22. WYNNE HA, LONG A: Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs). Br. J. Clin. Pharmacol. (1996) 42:253-256.
23. KATZ JN, DALTROY LH, BRENNAN TA, LIANG MH: Informed consent and the prescription of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. (1992) 35:1257-1263.
24. ENLUND H, VAINIO K, WALLENIUS S, POSTON JW: Adverse drug effects and the need for drug information. Med. Care (1991) 156:1414-1420.
25. BURNS E, WYLD PJ, BAX NDS: Doctors' and patients' perceptions of adverse drug reactions in a general medical and an anticoagulant clinic. J. R. Coll. Phys. Lond. (1988) 22:248-251.
26. ZIEGLER DK, MOSIER MC, BUERNAVER M et al.: How much information about adverse effects of medication do patients want from physicians? Arch. Intern. Med. (2001) 161:706-713.
27. EDWARDS A, ELWYN G, HOOD K, ATWELL C et al.: Patient-based outcome results from a cluster randomised trial of shared decision making skill development and use of risk communication aids in general practice. Fam. Pract. (2004) 21(4):347-354.
28. VOGT EM: Effective communication of drug safety information to patients and the public. Drug Saf. (2002) 25(5):313-321.